Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-1/PD-L1-IN-10 是一种口服有效的PD-1/PD-L1抑制剂 (IC50of 2.7 nM),显示出抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 456 | 现货 | ||
5 mg | ¥ 996 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 3,460 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 7,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,160 | 现货 |
产品描述 | PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. |
靶点活性 | PD-1/PD-L1:2.7 nM |
体外活性 |
PD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro even at the low concentration of 1 nM[1]. PD-1/PD-L1-IN-10 (compound B2) does not affect cell viability of LLC cells and lymph node T-cells[1]. PD-1/PD-L1-IN-10 (compound B2, 0-100 nM) stabilizes the PD-L1 protein in mouse Lewis lung carcinoma (LLC) cells. Especially, PD-1/PD-L1-IN-10 (compound B2) maintains the PD-L1 stability in a dose-dependent manner at 58 °C. Suggesting that PD-1/PD-L1-IN-10 (compound B2) could enter LLC cells and then directly binds to the PD-L1 protein[1]. |
体内活性 | PD-1/PD-L1-IN-10 (compound B2, 5 mg/kg, intragastric gavage) exhibits potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model. PD-1/PD-L1-IN-10 (compound B2) effectively blocks tumor cell proliferation and induces apoptosis in LLC tumor tissues.[1]. |
分子量 | 581.62 |
分子式 | C33H31N3O7 |
CAS No. | 2487550-41-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (171.93 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7193 mL | 8.5967 mL | 17.1934 mL | 42.9834 mL |
5 mM | 0.3439 mL | 1.7193 mL | 3.4387 mL | 8.5967 mL | |
10 mM | 0.1719 mL | 0.8597 mL | 1.7193 mL | 4.2983 mL | |
20 mM | 0.086 mL | 0.4298 mL | 0.8597 mL | 2.1492 mL | |
50 mM | 0.0344 mL | 0.1719 mL | 0.3439 mL | 0.8597 mL | |
100 mM | 0.0172 mL | 0.086 mL | 0.1719 mL | 0.4298 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PD-1/PD-L1-IN-10 2487550-41-2 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 Lewis T-lymphocyte tumor IFN-γ Inhibitor lung LLC inhibit PD1/PDL1IN10 PD 1/PD L1 IN 10 carcinoma PD-1/PD-L-1-IN-10 inhibitor